Investigational Drug Information for Sirna-027
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Sirna-027?
Sirna-027 is an investigational drug.
There have been 28 clinical trials for Sirna-027.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2016.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Adenocarcinoma, and Macular Degeneration. The leading clinical trial sponsors are Nitto Denko Corporation, National Cancer Institute (NCI), and Allergan.
There are three US patents protecting this investigational drug and two hundred and fifty-eight international patents.
Summary for Sirna-027
US Patents | 3 |
International Patents | 258 |
US Patent Applications | 0 |
WIPO Patent Applications | 0 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 2 (2016-01-01) |
Vendors | 0 |
Recent Clinical Trials for Sirna-027
Title | Sponsor | Phase |
---|---|---|
Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Rain Therapeutics Inc. | Phase 1/Phase 2 |
Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Medical University of South Carolina | Phase 1/Phase 2 |
Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19 | St. Petersburg Research Institute of Vaccines and Sera | Phase 2 |
Clinical Trial Summary for Sirna-027
Top disease conditions for Sirna-027
Top clinical trial sponsors for Sirna-027
US Patents for Sirna-027
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Sirna-027 | See Plans and Pricing | Recombinant vectors | Tocagen Inc. (San Diego, CA) | See Plans and Pricing |
Sirna-027 | See Plans and Pricing | Compositions and methods to control angiogenesis with cupredoxins | The Board of Trustees of the University of Illinois (Urbana, IL) | See Plans and Pricing |
Sirna-027 | See Plans and Pricing | Recombinant vectors | Tocagen Inc. (San Diego, CA) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Sirna-027
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Sirna-027 | Australia | AU2009303690 | 2028-09-26 | See Plans and Pricing |
Sirna-027 | Brazil | BRPI0919113 | 2028-09-26 | See Plans and Pricing |
Sirna-027 | Canada | CA2738472 | 2028-09-26 | See Plans and Pricing |
Sirna-027 | China | CN102227501 | 2028-09-26 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |